Responses to parliamentary questions
Question from Deputy Ken O'Flynn - PQ 10658-26
Deputy O'Flynn asked about the reimbursement of liraglutide (Saxenda) under the General Medical Services and Drugs Payment Schemes. Read the HSE response.
From: Communications and public affairs
Published: February 2026
Updated: March 2026
Documents
Question from Deputy Ken O'Flynn - PQ 10658-26
PDF, 636KB, 2 pages
Summary
To ask the Minister for Health to provide the eligibility criteria, prescribing settings, and clinical governance requirements applying to the managed access system under which liraglutide (Saxenda) is reimbursed under the General Medical Services and Drugs Payment Schemes; and to provide the number of patients approved under this pathway in each of the years 2024 and 2025, and to date in 2026.
This is a beta version - your feedback will help us to improve it